



ACMG THERAPEUTICS BULLETIN

Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)



Arthur Lenahan¹, Sho Yano², Brett Graham³, Kuntal Sen⁴; on behalf of the ACMG Therapeutics Committee^{5,*}

Disclaimer: This therapeutics bulletin is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this therapeutics bulletin is completely voluntary and does not necessarily assure a successful medical outcome. This therapeutics bulletin should not be considered inclusive of all proper procedures, treatments, and tests or exclusive of other procedures, treatments, and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure, treatment or test, clinicians should apply their own professional judgment to the specific clinical circumstances presented by the individual patient or specimen. Clinicians are encouraged to document the reasons for the use of a particular procedure, treatment, or test, whether or not it is in conformance with this therapeutics bulletin. Clinicians also are advised to take notice of the date this therapeutics bulletin was adopted, and to consider other medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures. Where individual authors are listed, the views expressed may not reflect those of authors' employers or affiliated institutions. The mention of any therapeutic approach, product, or sponsor in this therapeutics bulletin does not constitute endorsement or sponsorship by the American College of Medical Genetics and Genomics (ACMG). The ACMG does not endorse or recommend any specific therapeutic approach or product mentioned in this therapeutics bulletin.

ARTICLE INFO

Article history:

Received 30 August 2023

Accepted 31 August 2023

Available online 9 September 2023

Keywords:

Friedreich ataxia

Neuromuscular medicine

Omaveloxolone

Orphan drug

Precision medicine

Background

Friedreich ataxia (FRDA) is a genetic disorder caused by biallelic pathogenic variants in the *FXN* gene¹ encoding the frataxin protein. Frataxin is involved in several key pathways of mitochondrial function, particularly in iron homeostasis and the assembly of iron-sulfur complexes, which are involved in a wide range of cellular processes including respiration, replication, DNA repair, and translation. Frataxin has also been implicated in cellular antioxidant defenses dependent on Nrf2 activation.² FRDA involves slowly progressive neurologic dysfunction, including weakness, sensory loss, ataxia, and spasticity. Other frequently observed features include cardiomyopathy and diabetes.³

This article was a work product of the Therapeutics Committee of the ACMG and the Article Publishing Charge (APC) was waived. No industry sponsorship was received for this work.

The Board of Directors of the American College of Medical Genetics and Genomics approved this bulletin on 28 August 2023.

*Correspondence: ACMG. Email address: documents@acmg.net

Affiliations are at the end of the document.

doi: <https://doi.org/10.1016/j.gimo.2023.100832>

2949-7744/© 2023 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Figure 1 Simplified mechanism of action for omaveloxolone.

Management and Treatment

Consensus guidelines for management of FRDA were published by an international work group in 2014 with evidence-based grading.³ Management involves active treatment of spasticity; monitoring and bracing for scoliosis; physical, occupational and speech therapy; and audiometry. Guidelines also suggest surveillance for diabetes mellitus as well as cardiomyopathy and arrhythmias. Before 2023, there were no US Food and Drug Administration (FDA)-approved therapies with evidence for improvement in neurological function, quality of life, or cardiac function in FRDA.³ Past trials of idebenone, luvadaxistat, erythropoietin, deferiprone, interferon gamma-1b, and CoQ10 have not demonstrated clinical benefit.⁴

Newly Approved Therapy

Indication and approved treatment population

Omaveloxolone (trade name: SKYCLARYS) is a Nrf2 activator that increases cellular resilience to oxidative stress that has been FDA approved for patients with FRDA who are 16 years and older. Omaveloxolone received orphan drug, fast track, priority review, and rare pediatric disease

designations. Omaveloxolone is a semisynthetic triterpenoid administered orally once daily.

Mechanism of action

Omaveloxolone activates Nrf2, a regulator of oxidative stress response genes involved in FRDA (Figure 1). Nrf2 is normally suppressed by KEAP1, which targets it for degradation. Oxidative stresses disrupt KEAP1 interaction with Nrf2, allowing Nrf2 to activate expression of antioxidant enzymes. This leads to restoration of redox balance. In FRDA, Nrf2 is degraded prematurely. Omaveloxolone prevents ubiquitination of Nrf2, resulting in increased expression of antioxidant genes. Therefore, FRDA neurons exhibit hypersensitivity to oxidative stress, resulting in neuronal dysfunction and death.^{2,5}

Outcomes and efficacy

The MOXIe study (RTA 408 Capsules in Patients with FRDA) was a double-anonymized randomized placebo-controlled phase 2 trial. Part 1 was a study of 69 patients showing dose-dependent improvement of neurological function using the modified Friedreich's Ataxia Rating Scale (mFARS).^{6,7} Part 2 included 103 patients, 51 of whom received 150 mg omaveloxolone daily.⁸ The primary

outcome was mFARS score at 48 weeks. Omaveloxolone led to an improvement of -2.40 points compared with placebo ($P = 0.014$), as well as improvement from baseline (-1.55 , 95% CI $[-2.93$ to $-0.18]$).⁸ The treatment effect remained significant after 72 weeks of open-label extension.⁹ No difference was observed in cardiopulmonary function at 12 weeks.⁶

Adverse effects and toxicity

Adverse reactions among patients treated with omaveloxolone included upper respiratory infections, headache, diarrhea, mild increases in liver aminotransferases, nausea, arthralgia, and fatigue. Patients with laboratory evidence of liver inflammation did not show symptoms of acute liver injury. There are no boxed warnings for omaveloxolone.

Additional Considerations

No other clinical trials are ongoing currently for omaveloxolone. As of the time of this writing, multiple other clinical trials are in the early stages. Agents under investigation include rosuvastatin, methylprednisolone, micronized resveratrol, nicotinamide, artesunate, etravirine, and several novel biologics (www.clinicaltrials.gov). Among these, research is preliminary, and results are not yet available.¹⁰

Acknowledgments

The authors would like to thank Sandor Roberts, Sheri Poskanzer, Loren Peña, and Irene Chang from the ACMG Therapeutics Committee who helped with the selection of the authors and the review of the final manuscript. The authors were involved with the review of the data and the development of the manuscript.

Conflict of Interest

The authors declare no conflicts of interest.

Affiliations

¹Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA; ²Section of Pediatric Neurology, Department of Pediatrics, University of Chicago, Chicago, IL; ³Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN; ⁴Division of Neurogenetics and Neurodevelopmental Pediatrics, Center for Neuroscience and Behavioral Medicine, Children's National Hospital, Washington, DC; ⁵American College of Medical Genetics and Genomics, Bethesda, MD

References

1. Bidichandani SI, Delatycki MB. Friedreich ataxia. In: Adam MP, Mirzaa GM, Pagon RA, eds. *GeneReviews*. Seattle: University of Washington; 2017:1993-2023. December 18, 1998. Last update June 1, 2017.
2. Paupe V, Dassa EP, Goncalves S, et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. *PLoS ONE*. 2009;4(1):e4253. <http://doi.org/10.1371/journal.pone.0004253>
3. Corben LA, Collins V, Milne S, et al. Clinical management guidelines for Friedreich ataxia: best practice in rare diseases. *Orphanet J Rare Dis*. 2022;17(1):415. <http://doi.org/10.1186/s13023-022-02568-3>
4. Jain P, Badgular L, Spoorendonk J, Buesch K. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review. *Ther Adv Rare Dis*. 2022;3:26330040221139872. <http://doi.org/10.1177/26330040221139872>
5. D'Oria V, Petrini S, Travaglini L, et al. Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons. *Int J Mol Sci*. 2013;14(4):7853-7865. <http://doi.org/10.3390/ijms14047853>
6. Lynch DR, Farmer J, Hauser L, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. *Ann Clin Transl Neurol*. 2019;6(1):15-26. <http://doi.org/10.1002/actn3.660>
7. Rummey C, Harding IH, Delatycki MB, Tai G, Rezende T, Corben LA. Harmonizing results of ataxia rating scales: mFARS, SARA, and ICARS. *Ann Clin Transl Neurol*. 2022;9(12):2041-2046. <http://doi.org/10.1002/actn3.51686>
8. Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). *Ann Neurol*. 2021;89(2):212-225. <http://doi.org/10.1002/ana.25934>
9. Lynch DR, Chin MP, Boesch S, et al. Efficacy of omaveloxolone in Friedreich's ataxia: delayed-start analysis of the MOXIe Extension. *Mov Disord*. 2023;38(2):313-320. <http://doi.org/10.1002/mds.29286>
10. Rodden LN, Lynch DR. Designing phase II clinical trials in Friedreich ataxia. *Expert Opin Emerg Drugs*. 2021;26(4):415-423. <http://doi.org/10.1080/14728214.2021.1998452>